An interventional study of mHealth Educational Self-Management Application and Usual transitional care in Heart Failure, Self-care and Transitional Care, sponsored by Universidad de la Sabana. Not yet recruiting at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Universidad de la Sabana · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Heart Failure with a site in Colombia — 7 open to participants now, 9 under way, 5 of them phase 3. Heart Failure · Colombia.
Among the 39 studies in Heart Failure with a site in Colombia, this one is the 32nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 38th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →7 of the 39 studies in Heart Failure with a site in Colombia are open now. Recruiting first, the newest first:
Amgen · Sites in Colombia, United States, Argentina and 32 more countries
Ages 18–99
Boehringer Ingelheim · Sites in Colombia, United States, Argentina and 26 more countries
Ages 18+
Boehringer Ingelheim · Sites in Colombia, United States, Argentina and 27 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Colombia, United States, Belgium and 27 more countries
Ages 29 days–17 yrs
Clinica Cardio VID · Sites in Colombia
Ages 18+
A study can be open while its sites in Colombia have not opened yet or have stopped. Only those recruiting at a site in Colombia →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 21 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 3,388 across the 34 interventional studies, 2,169 across the 5 observational. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
Universidad de la Sabana is the lead sponsor of 23 studies on the registry; 8 are open to participants now.
Universidad de la Sabana has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Failure with a site in Colombia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07478081Universidad de la SabanamHealth Intervention to Support Self-care During the Hospital to Home Transition in Individuals With Heart Failure | 2027-06 |
| NCT07664189Clinica Cardio VIDLBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Heart Failure with a site in Colombia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a pilot randomized controlled trial designed to evaluate the feasibility, acceptability, usability, and preliminary efficacy of a mobile health (mHealth) educational self-management intervention for individuals with heart failure during the transition from hospital to home. Participants will be randomly assigned in a 1:1 ratio to receive either usual care alone or usual care plus the mHealth intervention.
The mobile application is designed to support heart failure self-care through tailored educational content, symptom self-monitoring, automated feedback, behavioral reinforcement messages, caregiver involvement, and secure communication with the healthcare team. The application is educational in nature and does not replace standard medical treatment.
A total of 30 participants will be enrolled and followed for 60 days after hospital discharge, with outcome assessments conducted at 30 and 60 days. Primary outcomes focus on feasibility, technology acceptance, and usability of the intervention. Secondary exploratory outcomes include changes in self-care behaviors, functional status, heart failure related hospital readmissions and natriuretic peptide levels. Results from this pilot study will inform the design of a future definitive randomized controlled trial.
This is an interventional, randomized, controlled, parallel-group pilot trial with a 1:1 allocation ratio designed to evaluate the feasibility, acceptability, usability, and preliminary efficacy of a mobile health (mHealth) educational self-management intervention for individuals with heart failure during the hospital-to-home transition. The study uses a single-blind design in which outcome assessors are blinded to group assignment. The intervention is behavioral and educational in nature; therefore, the study phase is classified as not applicable.
The study will be conducted at a tertiary cardiovascular referral institution. Participants will be recruited from inpatient cardiology services prior to hospital discharge and followed for 60 days after hospital discharge, with outcome assessments conducted at 30 and 60 days.
Eligible participants include adults aged 18 years or older with a diagnosis of heart failure (New York Heart Association class II or III), who are clinically stable at discharge, own a compatible smartphone, demonstrate basic digital literacy, and have an informal caregiver willing to support the intervention. Key exclusion criteria include life expectancy less than 6 months, severe cognitive impairment, inability to provide informed consent, or participation in another interventional study.
Participants will be randomly assigned (1:1) using computer-generated block randomization with variable block sizes of 4 and 6. The allocation sequence will be generated by an independent researcher not involved in recruitment or outcome assessment. Allocation concealment will be ensured through sequentially numbered, opaque, sealed envelopes.
Two study arms are defined:
Participants in the usual care group will receive standard hospital to home transitional care according to institutional protocols, including multidisciplinary discharge education, medication reconciliation, and scheduled outpatient follow-up.
Participants in the experimental group will receive usual care plus the mHealth educational self-management intervention. The intervention consists of a mobile application developed prior to study initiation and designed to strengthen heart failure self-care. Core components include tailored educational modules, symptom self-monitoring, automated feedback, behavioral reinforcement messages, caregiver integration, and secure communication with the healthcare team.
The intervention will be delivered over a 60-day period following hospital discharge. Implementation begins prior to discharge with application installation and guided education involving both the participant and caregiver. After discharge, the intervention includes intensive monitoring during week 1, reinforcement and on-demand contact during weeks 2-4, and automated monitoring with digital feedback from week 5 through day 60 post-discharge, with follow-up assessments conducted at 30 and 60 days..
Primary outcomes assess feasibility of trial procedures, technology acceptance using the technology acceptance model scale, and usability of the mobile application using the system usability scale and a user-centered cognitive walkthrough. Secondary exploratory outcomes include change in self-care measured with the Self Care of Heart Failure Index (SCHFI v7.2), heart failure-related hospital readmissions, change in New York Heart Association functional class, and change in NT-proBNP levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standard hospital to home transitional care, including multidisciplinary discharge education, medication reconciliation, and scheduled outpatient follow-up according to institutional protocols.
Other: Usual transitional care
Participants will receive a mobile health (mHealth) educational self-management intervention in addition to usual care. The intervention consists of a mobile application designed to support heart failure self-care through tailored educational modules, symptom self-monitoring, automated feedback, behavioral reinforcement messages, caregiver integration, and secure communication with the healthcare team over a 60-day period following hospital discharge.
Behavioral: mHealth Educational Self-Management Application
A structured mobile health educational and self-management intervention delivered through a smartphone application. The intervention provides tailored heart failure education, daily and weekly symptom monitoring, automated reinforcement messages, caregiver engagement tools, and communication support with the healthcare team. The intervention is educational in nature and does not function as a regulated medical device.
Standard multidisciplinary hospital discharge education, medication reconciliation, and scheduled outpatient follow-up provided according to institutional protocols.
Recruitment rate
Proportion of eligible participants who are enrolled and randomized in the trial
Time frame: From screening until completion of recruitment
Retention rate
Proportion of randomized participants who complete follow-up assessments
Time frame: 30 and 60 days post-discharge
Adherence to the mHealth intervention
Proportion of educational modules completed and symptom self-monitoring entries recorded in the application logs.
Time frame: 30 and 60 days post-discharge
Data completeness
Percentage of completed outcome assessments among enrolled participants
Time frame: 30 and 60 days post-discharge
Time required for enrollment and intervention delivery
Time required to complete enrollment procedures and initial intervention delivery, measured in minutes.
Time frame: At enrollment
Technology Acceptance of the Mobile Application (TAM)
Technology acceptance will be measured using the Technology Acceptance Model (TAM) scale, an 11 item instrument assessing perceived usefulness, perceived ease of use, and behavioral intention to use the application. Items are rated on a 5 point Likert scale (1 = strongly disagree to 5 = strongly agree). Results will be reported as mean total score and mean subscale scores.
Time frame: 60 days post-discharge
Usability of the Mobile Application
Usability will be assessed using two complementary methods: (a) System Usability Scale (SUS), a 10 item questionnaire scored from 0 to 100 and reported as mean total score and (b) User-Centered Cognitive Walkthrough (UC-CW), evaluating task completion rate, number and type of navigation errors, and functional understanding issues.
Time frame: 30 days post-discharge
Change in Self-Care (SCHFI v7.2)
Self-care will be measured using the Self-Care of Heart Failure Index (SCHFI v7.2), which provides standardized scores (0-100) for maintenance, symptom perception, and management subscales. The primary metric will be change from baseline, 30 days and 60 days post-discharge
Time frame: Baseline, 30 days and 60 days post-discharge
Heart Failure Related Hospital Readmissions
Number and proportion of participants readmitted due to heart failure decompensation, verified through institutional medical record review.
Time frame: 30 and 60 days post-discharge
Change in NYHA Functional Class
Change in New York Heart Association (NYHA) functional class (I-IV), reported as proportion improved, unchanged, or worsened from baseline, 30 days and 60 days post-discharge
Time frame: Baseline, 30 days and 60 days post-discharge
Change in NT-proBNP Levels
Change in NT-proBNP plasma levels (pg/mL), measured using institutional laboratory standard methods, reported as mean change from baseline to 30 days and 60 days post-discharge
Time frame: Baseline, 30 days and 60 days post-discharge
Plan to share: Yes — De-identified individual participant data will be shared, including demographic and baseline clinical variables, group assignment, feasibility outcomes, technology acceptance, usability measures, self-care outcomes, NYHA functional class, NT-proBNP levels, and heart failure-related readmissions. Data will be made available upon reasonable request from qualified investigators for academic and non-commercial research purposes.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will be available beginning 6 months after publication of the primary results and will remain available for a minimum of 5 years.
Access criteria: Qualified researchers may request access by contacting the principal investigator. Requests must include a brief proposal, analysis plan, and a data use agreement. Data will be shared in a de-identified format through a secure institutional repository.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Jun 2027, 15 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 15 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de la Sabana